1. New Lipid-Lowering Therapies

2. Challenges in the Post Statin Era

3. Identification of the Ideal Candidates

4. IMPROVE-IT No Signal of Adverse Consequence of Very Low LDL

5. GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound (GLAGOV)

6. New Lipid-Lowering Therapies

7. Statin Intolerance

8. Role of PCSK9 Inhibitors in Statin-Intolerant Patients*

9. Percent LDL-C Reduction vs Myalgia Rates Evolocumab

10. New Lipid-Lowering Therapies

11. TESLA Part B: Percent Change in UC LDL-C From Baseline to Week 12

12. LDL Levels in FH From a Lethal Disorder to a Manageable Dyslipidemia

13. Homozygous FH

14. New Lipid-Lowering Therapies

15. OSLER Program

16. Evolocumab OSLER Trial Cumulative Incidence of Cardiovascular Events*

17. ODYSSEY Long-term CVD Risk and Statin Use

18. ODYSSEY LONG TERM: Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

19. OSLER AEs by Achieved LDL-C

20. ODYSSEY LONG-TERM Study AEs

21. ODYSSEY OUTCOMES: Summary of AEs by Achieved LDL-C No. of Patients (%)

22. Abbreviations

23. Abbreviations (cont)

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)